What Is the IM032-041 Clinical
Research Study?
The IM032-041 is a clinical research study being led by dermatologist doctor Dr. José Hermenio Cavalcante Lima Filho to evaluate the effectiveness of the study drug BMS-986322 at different levels in treating patients with moderate-to-severe psoriasis.
How Will the IM032-041 Study Work?
If you meet eligibility criteria and choose to participate, you’ll receive a 12-week supply of experimental medication or a placebo, attending eight in-person appointments for health and psoriasis evaluations.
The study details will be thoroughly explained during the informed consent process, allowing questions and concerns. If you agree, you’ll need to sign the consent form before the initial screening tests.
Study Reviewed by
FAQs
Do I qualify for this study?
You may be eligible to participate in this study if you are 18 to 70 years of age, have been diagnosed with plaque psoriasis for at least six (6) months, and have plaques that cover at least 10% of your body. The skin on the palm of the hand, not including the fingers, makes up about 1% of our body total skin surface.
What is psoriasis?
Psoriasis is a chronic autoimmune skin condition that results in itchy, dry, raised skin patches (plaques) covered with gray or silver scales, commonly affecting the knees, elbows, trunk, and scalp, frequently, causing discomfort.
What are clinical research studies?
Clinical research studies, often referred to as clinical trials, are systematic investigations designed to evaluate the safety, efficacy, and optimal use of new medical treatments, interventions, or devices in humans. These studies play a crucial role in advancing medical knowledge and patient care, as they provide the scientific evidence needed to determine whether new treatments are more effective or safer than existing ones, or if they offer any other benefits.
Why should I participate in a clinical research study?
Participating in a clinical trial is a unique opportunity to play an active role in your own healthcare, potentially benefiting from cutting-edge treatments before they’re widely available. Beyond personal advantages, your participation can pave the way for medical breakthroughs that have the potential to change, and even save, lives in the years to come.
Who is the doctor involved in this research?
Dr. Lima, a distinguished immunologist and dermatologist trained at Harvard School of Public Health and at CURTIS, Massachusetts General Hospital, has held prestigious roles at the Michael G. DeGroote School of Medicine, McMaster University, including Associate Professor of Dermatology and, later, Head of the Division of Dermatology. In 2018, he founded and spearheaded Lima’s Excellence in Allergy and Dermatology (LEADER) Research, further amplifying his prominence in the field.
A prolific contributor to the realms of Immunodermatology, especially in Atopic Dermatitis, Hidradenitis Suppurativa, Psoriasis, Urticaria, Vitiligo, and Prurigo Nodularis, Dr. Lima published over 100 articles in specialized journals, has over 1,000 citations in ISI Web of Science, and has been involved as a Principal Investigator or Sub-PI in over 40 clinical trials.
Contact Us & Check Your Eligibility
Contact us to receive more information about this study.